First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors. Issue 2 (4th October 2017)

• Record Type: Journal Article
• Authors: Bédard, Philippe L.; Davies, Michael A.; Kopetz, Scott; Juric, Dejan; Shapiro, Geoffrey I.; Luke, Jason J.; Spreafico, Anna; Wu, Bin; Castell, Christelle; Gomez, Corinne; Cartot‐Cotton, Sylvaine; Mazuir, Florent; Dubar, Michel; Micallef, Sandrine; Demers, Brigitte; Flaherty, Keith T.
• Is Part Of: Cancer. Volume 124:Issue 2(2018)
• Page Start: 315
• Page End: 324
• Publication Date: 2017-10-04
• Subjects: advanced solid tumor -- pharmacodynamics -- pharmacokinetics -- phosphoinositide 3‐kinase (PI3K) -- SAR260301; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.31044
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: Phosphoinositide 3‐kinase (PI3K) β is the dominant isoform for PI3K activity in many phosphatase and tensin homolog (PTEN)‐deficient tumor models. This was a first‐in‐human study to determine the maximum tolerated dose, safety, pharmacokinetics (PK), pharmacodynamics, and preliminary activity of SAR260301, a potent PI3Kβ‐selective inhibitor (clinicaltrials.gov identifier NCT01673737). METHODS: Successive cohorts of patients with advanced solid tumors received increasing doses of oral SAR260301 according to a Bayesian escalation with an overdose‐control process based on the occurrence of dose‐limiting toxicity in the first 28‐day cycle. Adverse events, tumor response, PK, and the effect of food on PK were evaluated. Target engagement was assessed in platelets. Physiologically‐based PK modeling was used for exposure predictions. RESULTS: Twenty‐one patients received treatment at doses ranging from 100 mg once daily to 440 mg/m 2 twice daily. Dose‐limiting toxicities included 1 episode of grade 3 pneumonitis (400 mg twice daily) and 1 grade 3 γ‐glutamyltransferase increase (600 mg twice daily). The maximum tolerated dose was not reached. The most frequently occurring treatment‐related adverse events were nausea, vomiting, and diarrhea (14% each). Pharmacologically active concentrations were reached, but SAR260301 was rapidly cleared, and exposures associated with antitumor activity in preclinical models were not maintained at the highest dose tested. Food further decreased SAR260301 exposure. CONCLUSIONS: SAR260301 had an acceptable safety profile, but exposure sufficient to inhibit the PI3K pathway was unachievable because of rapid clearance, and clinical development was terminated. These results demonstrate the importance of PK and pharmacodynamic assessments in early drug development. Cancer 2018;124:315‐24 . © 2017 American Cancer Society . Abstract : This first‐in‐human study evaluates the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of SAR260301, a selective inhibitor of phosphoinositide 3‐kinase β. SAR260301 is well tolerated, but it cannot achieve exposure sufficient to inhibit the phosphoinositide 3‐kinase pathway because of rapid clearance; therefore, its clinical development has been terminated.